Total Payments
$1.1M
2024 Payments
$65,880
Companies
9
Transactions
435
Medicare Patients
10,956
Medicare Billing
$455,236
Payment Breakdown by Category
Consulting$663,880 (62.3%)
Research$280,468 (26.3%)
Travel$59,627 (5.6%)
Other$57,340 (5.4%)
Food & Beverage$4,040 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $663,880 | 186 | 62.3% |
| Unspecified | $280,468 | 108 | 26.3% |
| Travel and Lodging | $59,627 | 57 | 5.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $57,340 | 23 | 5.4% |
| Food and Beverage | $4,040 | 61 | 0.4% |
Payments by Type
General
$784,888
327 transactions
Research
$280,468
108 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $584,478 | 130 | $0 (2021) |
| Regeneron Pharmaceuticals, Inc. | $280,468 | 108 | $0 (2024) |
| Siemens Medical Solutions USA, Inc. | $109,237 | 129 | $0 (2024) |
| PFIZER INC. | $59,760 | 46 | $0 (2024) |
| BRACCO DIAGNOSTICS INC. | $16,915 | 10 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $11,776 | 4 | $0 (2021) |
| Incyte Corporation | $1,575 | 5 | $0 (2024) |
| GE HEALTHCARE | $1,007 | 2 | $0 (2021) |
| GUERBET LLC | $139.73 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $65,880 | 63 | PFIZER INC. ($36,175) |
| 2023 | $49,016 | 38 | PFIZER INC. ($23,585) |
| 2022 | $55,148 | 29 | Regeneron Pharmaceuticals, Inc. ($38,910) |
| 2021 | $389,326 | 68 | Merck Sharp & Dohme LLC ($281,198) |
| 2020 | $268,778 | 66 | Merck Sharp & Dohme Corporation ($194,789) |
| 2019 | $55,123 | 54 | Regeneron Pharmaceuticals, Inc. ($33,274) |
| 2018 | $87,937 | 75 | Merck Sharp & Dohme Corporation ($40,272) |
| 2017 | $94,146 | 42 | Merck Sharp & Dohme Corporation ($57,352) |
All Payment Transactions
435 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $2,040.00 | General |
| 12/04/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $990.00 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 11/21/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $3,640.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $480.00 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $175.00 | General |
| 10/25/2024 | Siemens Medical Solutions USA, Inc. | — | Travel and Lodging | In-kind items and services | $639.72 | General |
| 10/25/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $54.87 | General |
| 10/25/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $20.92 | General |
| 10/25/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $13.95 | General |
| 10/24/2024 | Siemens Medical Solutions USA, Inc. | — | Travel and Lodging | In-kind items and services | $207.83 | General |
| 10/24/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $86.10 | General |
| 10/24/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $76.73 | General |
| 10/24/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $24.02 | General |
| 10/23/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Siemens Medical Solutions USA, Inc. | — | Travel and Lodging | In-kind items and services | $207.83 | General |
| 10/23/2024 | Siemens Medical Solutions USA, Inc. | — | Food and Beverage | In-kind items and services | $56.79 | General |
| 10/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $3,230.00 | General |
| Category: ONCOLOGY | ||||||
| 10/18/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $60.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $960.00 | General |
| Category: ONCOLOGY | ||||||
| 10/03/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: ONCOLOGY | ||||||
| 09/20/2024 | PFIZER INC. | ELREXFIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,335.00 | General |
| Category: ONCOLOGY | ||||||
| 09/05/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $700.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A TWO-PART RANDOMIZED, PHASE 3 STUDY OF COMBINATIONS OF CEMIPLIMAB (ANTI-PD-1 ANTIBODY) AND PLATINUM-BASED DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $143,290 | 47 |
| A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 (ANTI-PD 1 ANTIBODY) VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1+NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $76,983 | 41 |
| A GLOBAL, RANDOMISED, PHASE 3, OPEN-LABEL STUDY OF REGN2810 ANTI-PD 1 ANTIBODY VERSUS PLATINUM BASED CHEMOTHERAPY IN FIRST LINE TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC PD L1NON-SMALL CELL LUNG CANCER | Regeneron Pharmaceuticals, Inc. | $33,045 | 9 |
| AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE PATIENTS WITH RECURRENT AND/OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK RECEIVING REGN2810 (ANTI-PD-1) | Regeneron Pharmaceuticals, Inc. | $14,170 | 5 |
| An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naive Unresectable Stage IIIIV Melanoma Patients Receiving REGN2810 Anti-PD-1 | Regeneron Pharmaceuticals, Inc. | $9,327 | 3 |
| AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND INDICATORS OF CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE UNRESECTABLE STAGE III/IV MELANOMA PATIENTS RECEIVING REGN2810 (ANTI-PD-1) | Regeneron Pharmaceuticals, Inc. | $2,014 | 1 |
| A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND COHORT EXPANSION FIRST-IN-HUMAN STUDY OF THE SAFETY, TOLERABILITY, ACTIVITY AND PHARMACOKINETICS OF REGN3767 (ANTI-LAG-3 MAB) ADMINISTERED ALONE OR IN COMBINATION WITH REGN2810 (ANTI-PD-1 MAB) IN PATIENTS WITH ADVANCED MALIGNANCIES | Regeneron Pharmaceuticals, Inc. | $1,410 | 1 |
| AN EXPLORATORY TUMOR BIOPSY-DRIVEN STUDY TO UNDERSTAND THE RELATIONSHIP BETWEEN BIOMARKERS AND INDICATORS OF CLINICAL RESPONSE IN IMMUNOMODULATORY TREATMENT-NAIVE UNRESECTABLE STAGE III IV MELANOMA PATIENTS RECEIVING REGN2810 ANTI-PD-1 | Regeneron Pharmaceuticals, Inc. | $229.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 2,526 | 2,638 | $934,999 | $100,560 |
| 2022 | 32 | 2,950 | 3,069 | $1.1M | $118,512 |
| 2021 | 30 | 2,874 | 3,007 | $1.0M | $119,801 |
| 2020 | 30 | 2,606 | 2,748 | $1.0M | $116,363 |
Total Patients
10,956
Total Services
11,462
Medicare Billing
$455,236
Procedure Codes
139
All Medicare Procedures & Services
139 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 557 | 585 | $348,075 | $35,823 | 10.3% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 355 | 373 | $139,502 | $14,062 | 10.1% |
| 74183 | Mri scan of abdomen before and after contrast | Facility | 2023 | 144 | 148 | $96,052 | $10,592 | 11.0% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Facility | 2023 | 116 | 118 | $90,270 | $8,300 | 9.2% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Facility | 2023 | 108 | 111 | $55,167 | $6,597 | 12.0% |
| 72197 | Mri scan of pelvis before and after contrast | Facility | 2023 | 54 | 54 | $35,046 | $3,838 | 10.9% |
| 76376 | 3d radiographic procedure | Facility | 2023 | 432 | 449 | $23,797 | $3,064 | 12.9% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 38 | 38 | $22,610 | $2,527 | 11.2% |
| 74018 | X-ray of abdomen, 1 view | Facility | 2023 | 170 | 207 | $7,452 | $1,331 | 17.9% |
| 72197 | Mri scan of pelvis before and after contrast | Office | 2023 | 17 | 17 | $11,033 | $1,140 | 10.3% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Facility | 2023 | 39 | 39 | $3,822 | $1,018 | 26.6% |
| 71250 | Ct scan of chest without contrast | Facility | 2023 | 27 | 27 | $9,045 | $1,013 | 11.2% |
| 74181 | Mri scan of abdomen without contrast | Facility | 2023 | 23 | 23 | $12,075 | $1,012 | 8.4% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Facility | 2023 | 37 | 37 | $6,919 | $938.04 | 13.6% |
| 74160 | Ct scan of abdomen with contrast | Facility | 2023 | 23 | 23 | $9,131 | $924.36 | 10.1% |
| 71260 | Ct scan of chest with contrast | Office | 2023 | 21 | 21 | $7,854 | $849.87 | 10.8% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Facility | 2023 | 34 | 34 | $5,576 | $842.60 | 15.1% |
| 93975 | Complete ultrasound of abdomen and pelvis artery and vein blood flow | Facility | 2023 | 19 | 19 | $5,852 | $757.14 | 12.9% |
| 74170 | Ct scan of abdomen before and after contrast | Facility | 2023 | 15 | 15 | $7,650 | $724.07 | 9.5% |
| 93971 | Ultrasound study of one arm or leg veins with compression and maneuvers | Facility | 2023 | 44 | 44 | $4,796 | $701.34 | 14.6% |
| 76705 | Limited ultrasound scan of abdomen | Facility | 2023 | 33 | 33 | $5,214 | $652.25 | 12.5% |
| 76100 | X-ray of body plane | Facility | 2023 | 34 | 34 | $4,114 | $581.88 | 14.1% |
| 76776 | Ultrasound scan of transplanted kidney | Facility | 2023 | 18 | 19 | $3,610 | $520.80 | 14.4% |
| 76700 | Complete ultrasound scan of abdomen | Facility | 2023 | 19 | 20 | $3,920 | $518.70 | 13.2% |
| 76536 | Ultrasound scan of head and neck soft tissue | Facility | 2023 | 25 | 25 | $3,300 | $499.92 | 15.1% |
About Dr. Daniele Marin, MD
Dr. Daniele Marin, MD is a Diagnostic Radiology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/27/2011. The National Provider Identifier (NPI) number assigned to this provider is 1407152283.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniele Marin, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $65,880 received in 2024. These payments were reported across 435 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($663,880).
As a Medicare-enrolled provider, Marin has provided services to 10,956 Medicare beneficiaries, totaling 11,462 services with total Medicare billing of $455,236. Data is available for 4 years (2020–2023), covering 139 distinct procedure/service records.
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Durham, NC
- Active Since 01/27/2011
- Last Updated 01/27/2011
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1407152283
Products in Payments
- LIBTAYO (Biological) $271,141
- LENVIMA (Drug) $221,450
- KEYTRUDA (Biological) $196,000
- MK-7339 (Drug) $58,135
- ELREXFIO (Drug) $57,320
- Non-Product Specific (Device) $19,565
- NAEOTOM Alpha (Device) $18,421
- ISOVUE (Drug) $12,396
- SOMATOM Force (Device) $10,506
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $9,327
- SOMATOM Drive (Device) $7,088
- SOMATOM Flash (Device) $6,307
- Multihance (Drug) $4,306
- SOMATOM AS (Device) $1,500
- V937 (Biological) $1,083
- REVOLUTION (Device) $988.94
- MAGNETOM Skyra (Device) $427.07
- SOMATOM Definition (Device) $354.59
- NEXO (Drug) $213.78
- CONTRAST MEDIA INJECTORS (Device) $139.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Durham
Dr. Rendon Nelson, M.d, M.D
Diagnostic Radiology — Payments: $1.7M
Diagnostic Radiology $1.7M
Dr. Paul Suhocki, Md, MD
Diagnostic Radiology — Payments: $354,598
Diagnostic Radiology $354,598
Rajan Gupta, M.d, M.D
Diagnostic Radiology — Payments: $185,794
Diagnostic Radiology $185,794
Dr. David Enterline, M.d, M.D
Diagnostic Radiology — Payments: $113,728
Diagnostic Radiology $113,728
Dr. Shelley Weiner, M.d, M.D
Diagnostic Radiology — Payments: $104,554
Diagnostic Radiology $104,554
Derek Nguyen
Diagnostic Radiology — Payments: $71,605
Diagnostic Radiology $71,605